论文部分内容阅读
目的探讨血清可溶性细胞表面黏附分子(sCD44v6)在结、直肠癌中的临床应用价值。方法96例不同Dukes,分期结、直肠癌患者和24例健康者,分别采用酶联免疫吸附试验(ELISA)定量检测其血清可溶性sCD44v6浓度,时间分辨免疫荧光法检测血清CEA浓度;并结合临床资料进行分析。结果结、直肠癌患者sCD44v6浓度为275.3±115.8ng/ml,明显高于健康对照组(61.3±7.8ng/ml,P<0.05),若以健康对照组的x+2s(76.9ng/ml)作为正常上限值,其阳性率为73.96%;sCD44v6水平随癌肿Dukes’分期的升级和肿瘤细胞的转移而呈现递增趋势,各组之间比较差异有显著性(P<0.05)。与CEA相比,sCD44v6水平在反映癌组织浸润和转移程度上更直接、敏感。结论结、直肠癌患者sCD44v6水平和阳性率均显著增高,并与肿瘤的分期和扩散转移程度密切相关;术前sCD44v6水平检测可作为结、直肠癌患者病程和转移预测的一个重要指标
Objective To investigate the clinical value of serum soluble cell surface adhesion molecule (sCD44v6) in colorectal cancer. Methods Serum soluble sCD44v6 levels were determined by enzyme-linked immunosorbent assay (ELISA) in 96 patients with different Dukes staging, rectal cancer and 24 healthy controls. Serum CEA levels were measured by time-resolved immunofluorescence. Combined with clinical data Analyze. Results The sCD44v6 concentration in rectal cancer patients was 275.3 ± 115.8ng / ml, which was significantly higher than that in healthy controls (61.3 ± 7.8ng / ml, P <0.05) The positive rate was 73.96%. The level of sCD44v6 showed an increasing trend with the progression of Dukes’ staging of cancer and the metastasis of tumor cells. There was significant difference between the groups (P <0.05). Compared with CEA, sCD44v6 level is more direct and sensitive in reflecting the degree of infiltration and metastasis of cancer tissue. Conclusion The levels of sCD44v6 and the positive rate in patients with colorectal cancer are significantly increased, which are closely related to the stage of the tumor and the degree of spread and metastasis. Preoperative sCD44v6 level can be used as an important indicator of the course of disease and metastasis in patients with colorectal cancer